Table 1.
Baseline characteristics of comparative studies
| Authors and year | Design | Group | Laser power (W) | No of patients | Age (years) | Prostate size (mL) | IPSS | Qmax (mL/s) | PVR (mL) | QoL | IIEF | Follow-up (months) | LE | Study quality |
| Kumar et al, 201324 | RCT | PVP | 120 | 58 | 64.58±6.64 | 52.79±16.13 | 20.05±2.75 | 6.68±2.00 | 143.35±52.67 | 3.60±1.01 | 16.65±2.80 | 12 | 2a | 3* |
| TURP | 60 | 63.68±6.57 | 52.20±15.93 | 20.71±2.68 | 7.00±1.97 | 139.25±54.28 | 3.73±0.97 | 16.95±2.86 | ||||||
| Lukacs et al 2012 2 | RCT | PVP | 120 | 68 | 66.9±7.8 | 50.54±16.53 | 22 (17–26)% | 7.79±2.75 | 89.5 (30, 158)% | 70 (68, 80)% | 12 | 2a | 3* | |
| TURP | 68 | 67.6±7.6 | 50.11±14.73 | 20 (15–23)% | 7.76±2.64 | 75 (28,126)% | 75 (65, 85)% | |||||||
| Pereira-Correia et al 201225 | RCT | PVP | 120 | 10 | 66.4 (52, 76)$ | 43.4 (30, 58)$ | 22 (9, 33)$ | 10 (3, 18)$ | 150 (25, 250)$ | 23 (22, 24)$ | 24 | 2a | 2* | |
| TURP | 10 | 63.5 (56, 78)$ | 47 (30, 60)$ | 25 (15, 31)$ | 6.4 (4,11)$ | 177 (50, 300)$ | 23 (22, 25)$ | |||||||
| Capitan et al 20117 | RCT | PVP | 120 | 50 | 69.8±8.44 | 51.29±14.72 | 23.74±5.24 | 8.03±3.14 | 4.52±0.27 | 12 | 2a | 3* | ||
| TURP | 50 | 67.7±6.7 | 53.10±13.75 | 23.52±4.38 | 3.88±2.71 | 4.14±1.06 | ||||||||
| Al-Ansari et al 201026 | RCT | PVP | 120 | 60 | 66.3±9.4 | 61.8±22 | 27.2±2.3 | 6.9±2.2 | 53.2±25 | 36 | 2a | 3* | ||
| TURP | 60 | 67.1±8 | 60.3±20 | 27.9±2.7 | 6.4±2 | 57±21 | ||||||||
| Xue et al 201327 | RCT | PVP | 120 | 100 | 72.1±11.3 | 65.8±23.6 | 23.0±5.1 | 8.0±3.6 | 148.3±101.6 | 4.2±0.9 | 36 | 2a | 2* | |
| TURP | 100 | 71.0±10.8 | 67.3±24.7 | 23.2±5.0 | 8.2±3.8 | 151.1±105.2 | 4.3±0.8 | |||||||
| Horasanli et al 200838 | RCT | PVP | 80 | 39 | 69.2±7.1 | 86.1±8.8 | 18.9±5.1 | 8.6±5.2 | 183±50.1 | 19.9±5.1 | 6 | 2a | 2* | |
| TURP | 37 | 68.3±6.7 | 88±9.2 | 20.2±6.8 | 9.2±5.6 | 176.9±45.3 | 20.1±5.5 | |||||||
| Mohanty et al 201228 | RCT | PVP | 80 | 60 | 66.68±8.62 | 44.77±14.09 | 19.98±3.27 | 7.41±2.07 | 145.8±70.33 | 3.97±0.82 | 17.98±3.55 | 12 | 2a | 3* |
| TURP | 57 | 65.74±9.09 | 49.02±15.93 | 20.88±3.87 | 6.75±1.63 | 143.23±65.96 | 3.91±0.78 | 17.40±4.76 | ||||||
| Bouchier-Hayes et al 200911 | RCT | PVP | 80 | 60 | >50 | 25.28±5.93 | 8.81±2.55 | 129.2±155.7 111.3±113.7 | 4.74±1.23 | 12 | 2a | 3* | ||
| TURP | 59 | 25.41±5.72 | 8.86±2.99 | 5.08±0.94 | ||||||||||
| Bachmann et al 201410 | RCT | PVP | 180 | 136 | 65.9±6.8 | 48.6±19.2 | 21.2±5.9 | 9.5±3.0 | 110.1±88.5 | 4.6±1.1 | 13.2±7.6 | 6 | 2a | 3* |
| TURP | 133 | 65.4±6.6 | 46.2±19.1 | 21.7±6.4 | 9.9±3.5 | 109.8±103.9 | 4.5±1.4 | 13.7±7.5 | ||||||
| Bachmann et al 201529 | RCT | PVP | 180 | 136 | 65.9±6.8 | 48.6±19.2 | 21.2±5.9 | 9.5±3.0 | 110.1±88.5 | 4.6±1.1 | 13.2±7.6 | 12 | 2a | 2* |
| TURP | 133 | 65.4±6.6 | 46.2±19.1 | 21.7±6.4 | 9.9±3.5 | 109.8±103.9 | 4.5±1.4 | 13.7±7.5 | ||||||
| Thomas et al 201630 | RCT | PVP | 180 | 136 | 65.9±6.8 | 48.6±19.2 | 21.2±5.9 | 9.5±3.0 | 110.1±88.5 | 4.6±1.1 | 13.2±7.6 | 24 | 2a | 3* |
| TURP | 133 | 65.4±6.6 | 46.2±19.1 | 21.7±6.4 | 9.9±3.5 | 109.8±103.9 | 4.5±1.4 | 13.7±7.5 | ||||||
| Telli et al 201532 | RCT | PVP | 120 | 39 | 67 (51, 87)$ | 60 (41, 75)$ | 20 (12, 30)$ | 10.6 (5, 17)$ | 60 (20, 220)$ | 24 | 2a | 2* | ||
| TURP | 62 | 69 (56, 87)$ | 55 (40, 72)$ | 19 (10, 31)$ | 12.5 (3, 21)$ | 65 (10, 220)$ | ||||||||
| Kumar et al 201631 | RCT | PVP | 120 | 58 | 64.58±6.64 | 52.79±16.13 | 20.05±2.75 | 6.68±2.00 | 143.35±52.67 | 3.60±1.01 | 16.65±2.80 | 36 | 2a | 2* |
| TURP | 60 | 63.68±6.57 | 52.20±15.93 | 20.71±2.68 | 7.00±1.97 | 139.25±54.28 | 3.73±0.97 | 16.95±2.86 | ||||||
| Mordasini et al 201839 | RCT | PVP | 80 | 112 | 68.4±8.7 | 36.1±11.5 | 20.3±7.0 | 8.9±4.1 | 91.1±88.3 | 4.2±1.1 | 60 | 2a | 2* | |
| TURP | 126 | 67.6±8.4 | 37.9±14.3 | 20.4±7.5 | 8.5±4.6 | 114.5±136.4 | 4.3±14 | |||||||
| Chen et al 2011 | PCS | PVP | 160 | 57 | 69.5±7.4 | 60.2±27.8 | 19.7±6.0 | 6.9±4.0 | 93.7±79.7 | 6 | 2b | 9† | ||
| TURP | 51 | 67.1±6.9 | 58.3±26.2 | 21.8±7.3 | 6.8±2.3 | 102.2±70.1 | ||||||||
| Bachmann et al 200537 | PCS | PVP | 37 | 71.0±9.3 | 65.1±36.9 | 18.1±5.9 | 6.9±2.2 | 146.1±106.9 120.7±49.0 | 3.3±1.7 | 6 | 2b | 9† | ||
| TURP | 64 | 68.7±7.9 | 48.9±21.2 | 17.3±6.3 | 6.9±2.2 | 3.4±1.6 | ||||||||
| Ruszat et al 20088 | PCS | PVP | 80 | 113 | 62.3±5.0 | 56.3±27.4 | 20±6.4 | 8.5±4.1 | 203±226 | 24 | 2b | 9† | ||
| TURP | 75 | 61.7±5.5 | 45.3±21.0 | 19±6.9 | 9.8±5.0 | 104±108 | ||||||||
| PVP | 91 | 75.0±2.8 | 64.8±26.8 | 18.6±5.8 | 7.3±2.7 | 215±247 | ||||||||
| TURP | 40 | 74.0±2.6 | 54.2±21.2 | 16.0±7.1 | 9.2±5.4 | 124±141 | ||||||||
| PVP | 65 | 84.3±3.1 | 69.3±32.7 | 14.1±7.4 | 7.1±4.2 | 200±219 | ||||||||
| TURP | 12 | 82.4±2.8 | 44.9±22.1 | 15.5±6.7 | 7.6±3.9 | 231±350 | ||||||||
| Tasci et al 200833 | PCS | PVP | 40 | 71.8±5.9 | 108.4±15.8 | 22.3±5.6 | 6.2±2.2 | 116.5±60.5 | 3.6±0.7 | 24 | 2b | 9† | ||
| TURP | 41 | 70.1±5.4 | 104.2±12.5 | 22.6±3.9 | 6.5±1.8 | 110.7±59.8 | 3.5±0.6 | |||||||
| Tugcu et al 200833 | PCS | PVP | 112 | 67.5±7.4 | 49.1±11.9 | 17.9±4.9 | 6.9±1.9 | 107.9±63.0 100.3±57.1 | 3.4±0.6 | 24 | 2b | 9† | ||
| TURP | 98 | 66.3±7.9 | 47.7±8.4 | 17.7±3.5 | 7.2±1.7 | 3.4±0.5 | ||||||||
| Nomura et al 200935 | PCS | PVP | 80 | 78 | 72.0 (67.0, 78.0)$ | 50.5 (38.6, 70.3)$ | 23 (17, 27)$ | 6.8 (5.2, 9.5)$ | 69 (31, 139)$ | 5 (5, 6)$ | 12 | 2b | 9† | |
| TURP | 51 | 70.5 (66.5, 76.0)$ | 42.8 (34.6, 54.0)$ | 22 (16, 27)$ | 7.3 (5.3, 10.2)$ | 60 (31, 140)$ | 5 (4, 5)$ | |||||||
| Guo et al 201536 | PCS | PVP | 80 | 257 | 69.7±8.9 66.4±8.4 | 52.3±19.3 44.2±19.1 | 19.4±6.3 18.4±6.3 | 8.3±6.0 | 119.5±83.8 95.6±98.4 | 3.7±1.7 3.7±1.3 | 60 | 2b | 9† | |
| TURP | 104 | 10.0±5.2 |
Continuous variables were expressed as (mean±SD), mean (range)$ or median (IQR)%.
Bachmann et al, 201410 Bachmann et al, 2015 and30 Thomas et al, 2016 are from the same trials in different period.24 Kumar et al, 2013 and Kumar et al, 2016 are from the same trials in different period.
*Using Jadad scale (score from 0 to 5).
†Using Newcastle-Ottawa Scale (score from 0 to 9).
IIEF, international index of erectile function; IPSS, International Prostate Symptom Score;LE, level of evidence; PCS, prospective cohort study; PVP, photoselective vaporisation of the prostate; PVR, postvoid residual volume; Qmax, maximum flow rate; QoL, quality of life;RCT, randomised controlled trial; TURP, transurethral resection of the prostate.